NYSE · VRTX
Healthcare · Biotechnology
$541.69
Down-$5.86 (-1.07%)
Updated Aug 30, 2026, 5:59 AM
SID Score
6.2/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
VRTX closed at $541.69 after 20 trading sessions, up 15.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $547.09 | $549.57 | $540.08 | $541.69 | 886.92K |
| Aug 27, 2026 | $540.08 | $550.83 | $540.08 | $547.55 | 844.62K |
| Aug 26, 2026 | $549.84 | $553.47 | $546.235 | $547.29 | 834.38K |
| Aug 25, 2026 | $545.53 | $555.69 | $543.75 | $552.85 | 775.04K |
| Aug 24, 2026 | $548.98 | $550.615 | $542.42 | $547.59 | 767.49K |
| Aug 21, 2026 | $545.10 | $555.32 | $540.70 | $548.05 | 1.07M |
| Aug 20, 2026 | $543.78 | $548.985 | $538.27 | $540.26 | 1.06M |
| Aug 19, 2026 | $537.47 | $553.69 | $532.55 | $552.06 | 1.44M |
| Aug 18, 2026 | $520.00 | $533.78 | $517.3401 | $528.19 | 1.5M |
| Aug 17, 2026 | $503.87 | $517.84 | $502.53 | $515.55 | 1.11M |
| Aug 14, 2026 | $511.41 | $513.6397 | $502.29 | $505.75 | 1.13M |
| Aug 13, 2026 | $528.68 | $529.00 | $515.74 | $516.44 | 863.53K |
| Aug 12, 2026 | $527.00 | $531.2159 | $520.08 | $525.73 | 1.05M |
| Aug 11, 2026 | $525.02 | $532.23 | $522.0102 | $529.65 | 1.07M |
| Aug 10, 2026 | $539.50 | $546.17 | $519.82 | $523.91 | 2.68M |
| Aug 7, 2026 | $487.11 | $497.395 | $482.10 | $496.07 | 992.49K |
| Aug 6, 2026 | $490.91 | $492.40 | $480.86 | $484.03 | 1.02M |
| Aug 5, 2026 | $487.52 | $491.9475 | $479.02 | $484.83 | 1.38M |
| Aug 4, 2026 | $471.29 | $488.04 | $465.51 | $478.705 | 2.03M |
| Aug 3, 2026 | $480.00 | $483.36 | $468.14 | $470.72 | 1.51M |
The latest Smart Investors Daily articles mentioning VRTX.
VRTX research
Company profile and research snapshot.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Truist Securities | Buy | — |
| Aug 5, 2026 | Barclays | Overweight | — |
| Aug 4, 2026 | TD Cowen | Buy | — |
| Aug 4, 2026 | Canaccord Genuity | Hold | — |
| Aug 4, 2026 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 27, 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals has a market
Yahoo · Aug 26, 2026
BOSTON, August 26, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences.
Yahoo · Aug 26, 2026
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
Yahoo · Aug 26, 2026
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VRTX.
